Elysia Larson

Dana-Farber Cancer Institute

Boston, Massachusetts - 02115

CLINICAL TRIALS 1
CONDITIONS3
INTERVENTIONS3
SINCE2008

Evaluation of the Efficacy and Safety of [18F]-ML-10 as a PET Imaging Radiotracer in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

November 2008 - October 2010

Brain Neoplasms

Neoplasms

Neoplasm Metastasis

Positron Emission Tomography

2-(5-Fluoro-Pentyl)-2-Methyl-Malonic-Acid ([18f]-Ml-10)

Stereotactic Radio-Surgery (Srs) Therapy

Learn about TrialX Patient Recruitment services

Massimo Loda, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Suzanne Shusterman

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Childrens Hospital Boston, Dana-Farber Cancer Institute. Children's Hospital Boston

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute Dana Farber / Brigham and Women's Cancer Center Dana-Farber Cancer Institute, Center for Neuro-Oncology Dana-Farber Cancer Instiute

Lewis B. Silverman, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute and Children's Hospital Dana Faber Cancer Institute, Children's Hospital, Dept. of Pediatric Oncology Children's Hospital Boston Dana-Farber Cancer Institute

Elysia Larson

Dana-Farber Cancer Institute

Massimo Loda, MD

Suzanne Shusterman

Patrick Y. Wen, MD

Lewis B. Silverman, MD

Kay Kehoe, Coordinator

Jennifer Brown, MD

Rachel A. Freedman

Edwin P. Alyea, MD

F. Stephen Hodi, MD

Beth A. Overmoyer, MD, FACP